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ARTICLE
Semimechanistic Clearance Models of Oncology 
Biotherapeutics and Impact of Study Design: Cetuximab 
as a Case Study
Ana-Marija Grisic1,2,3,†, Akash Khandelwal3,*, Mauro Bertolino3, Wilhelm Huisinga4, Pascal Girard5,‡ and Charlotte Kloft1,‡
This study aimed to explore the currently competing and new semimechanistic clearance models for monoclonal antibod-
ies and the impact of clearance model misspecification on exposure metrics under different study designs exemplified 
for cetuximab. Six clearance models were investigated under four different study designs (sampling density and single/
multiple-dose levels) using a rich data set from two cetuximab clinical trials (226 patients with metastatic colorectal can-
cer) and using the nonlinear mixed-effects modeling approach. A two-compartment model with parallel Michaelis–Menten 
and time-decreasing linear clearance adequately described the data, the latter being related to post-treatment response. 
With respect to bias in exposure metrics, the simplified time-varying linear clearance (CL) model was the best alternative. 
Time-variance of the linear CL component should be considered for biotherapeutics if response impacts pharmacokinetics. 
Rich sampling at steady-state was crucial for unbiased estimation of Michaelis–Menten elimination in case of the reference 
(parallel Michaelis–Menten and time-varying linear CL) model.
The emergence of new biologic therapies has led to dra-
matic improvement in the survival of patients with cancer.1 
However, a fully mechanistic understanding of the behav-
ior of monoclonal antibodies (mAbs) is still lacking, as their 
distribution and elimination are subject to complex phar-
macokinetics (PKs) that may change over time2 due to their 
protein nature with high affinity to their pharmacological tar-
get. Therefore, a quantitative description of their PK profile, 
especially clearance (CL), is a challenging task. The elim-
ination of mAbs is expected to comprise target-mediated 
drug disposition (TMDD; saturated at higher exposure and 
nonlinear/linear at lower concentrations) and nonspecific 
CL, which may be linear, nonlinear, and/or time-dependent, 
so both linear and nonlinear clearance are physiologically 
possible. However, quantification of each of these compo-
nents in a model is highly dependent on the data (i.e., the 
sampling scheme and dose range investigated), potentially 
leading to identification of different models for the same 
drug.
The mAbs targeting the epidermal growth factor re-
ceptor (EGFR) are among the most successful targeted 
therapies for patients with rat sarcoma proto-oncogene 
(RAS) wild-type metastatic colorectal cancer (mCRC), one 
of the most common causes of cancer death worldwide.3 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Characterization of complex clinical pharmacokinetics 
(PK) of monoclonal antibodies (mAbs) is hindered by limited 
availability of informative PK data over a wide dose range.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  This study explored semi-mechanistic clearance (CL) 
models for mAbs and implications of study design differ-
ences on identifiability of the CL models.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This analysis provides a population PK model incor-
porating both time-varying CL, related to treatment 
response, and target-mediated drug disposition (TMDD) 
component, and stresses the importance of informing the 
population models with rich data.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,  
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  Time-variance of CL in addition to TMDD should be 
considered for biotherapeutics if response impacts PK. 
Informing PK analyses with rich data (i.e., through pool-
ing data from multiple clinical trials at later stages of drug 
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Availability of rich PK data sets for cetuximab (Erbitux; 
Merck KGaA, Darmstadt, Germany) approved in mCRC 
offered us the opportunity to reconciliate the different 
published population PK models for this mAb, which dif-
fer in the elimination model of the compound. The first 
published model considered only Michaelis–Menten elim-
ination4; then, Azzopardi et al. proposed a parallel linear 
and zero-order elimination,5 and others found a simple 
linear elimination.6
To explore different semimechanistic CL models for mAbs 
and investigate implications of study design differences on 
identifiability of the CL models, we conducted a population 
PK analysis on a pooled data set, using cetuximab as a case 
study. The objectives of this study were to: (1) refine the 
population PK models of cetuximab in patients with mCRC 
taking into account the TMDD of the biologic therapy; while 
also (2) comparing mechanistically plausible CL implemen-
tations (including linear, nonlinear, and time-varying CL) and 
test how response may or may not interfere with PK; and (3) 
investigate implications of study designs typical for various 
phases of drug development on the model performance and 
parameter identifiability.
Figure 1 Overview of the analyzed clinical trials: a phase I (PhI) trial7 and EVEREST trial.8 (a) Dosing algorithm; (b) pharmacokinetic 
sampling schedule. The PhI trial comprised two arms. In arm A, the patients received the approved dosing regimen (ADR). In arm B, 
after the initial 2-hour infusion of 400 mg/m2, the patients received 2-hour 400 mg/m2, 2.5-hour 500 mg/m2, 3-hour 600 mg/m2, or 3.5-
hour 700 mg/m2 infusions q2w. In the EVEREST trial, all patients initially received cetuximab ADR in combination with irinotecan; after 
3 weeks of treatment the patients eligible for randomization either continued receiving ADR (group A) or underwent dose escalation 
(group B), whereas the patients not eligible for randomization continued the treatment with ADR (group C). In group B, with each 
dose increase of 50 mg/m2 the dense sampling interval was shifted, denoted as “(B…)” for EVEREST in the figure. For all arms/
groups the sampling continued until the patients dropped out of the study or until the study end. ADR, approved dosing regimen for 
cetuximab (2-hour 400 mg/m2, 1-hour 250 mg/m2 once weekly); FOLFIRI, co-medication with irinotecan (30–90 minutes of 180 mg/
m2) + 5-fluorouracil (180 mg/m2 bolus and 2400 mg/m2 as infusion over 46 hours) + folic acid (2-hour 400 mg/m2); q2w, every 2 weeks.
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METHODS
Clinical trial design and population
The data for this analysis originate from two multicenter 
clinical trials in patients with advanced mCRC (a phase 
I (PhI) trial7 and EVEREST8). The PhI trial was a phase I, 
open-label, multicenter trial designed to evaluate the PK 
and pharmacodynamics (PD) of cetuximab. The EVEREST 
trial was a phase I/II, open-label, randomized, controlled, 
multicenter trial aiming to evaluate PK and PD of cetuximab 
dose escalation as well as pharmacogenomic and phar-
macogenetic aspects. Full study descriptions are reported 
elsewhere.7,8
Treatment administration
In the PhI trial, patients received intravenous cetuximab 
monotherapy for the first 6  weeks, followed by cetux-
imab-FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) 
co-therapy (Figure 1a). The patients were assigned to the 
following treatment groups:
1. Initial 400  mg/m2 cetuximab infusion, followed by 
weekly dose of 250 mg/m2 (approved dosing regimen 
(ADR)) (arm A);
2. Cetuximab dose of 400 mg/m2 every 2 weeks (q2w),
3. Cetuximab dose of 500 mg/m2 q2w,
4. Cetuximab dose of 600 mg/m2 q2w, and
5. Cetuximab dose of 700 mg/m2 q2w (arm B)
Starting from week 7, in addition to cetuximab, all patients 
started FOLFIRI treatment, which comprises irinotecan 
(180 mg/m2), 5-fluorouracil (180 mg/m2 bolus and 46-hour 
2400  mg/m2 infusion), and folic acid (2-hour 400  mg/m2 
infusion). The treatment was continued until disease pro-
gression or an unacceptable adverse event.
In the EVEREST trial (Figure 1a), all patients received 
cetuximab ADR-irinotecan co-therapy for the first 3 weeks. 
On the fourth week, patients who had not required irinote-
can discontinuation and had not experienced skin reaction 
of grade >  1 or any other cetuximab-related toxicity of 
grade > 2 were randomized to continue the ADR (group A) 
or undergo cetuximab dose escalation (group B). The dose 
escalation comprised increasing the cetuximab dose by 
50  mg/m2/week up to the maximum dose of 500  mg/m2/
week. Patients not eligible for randomization continued 
the cetuximab ADR-irinotecan treatment (group C). The 
treatment was continued until disease progression or an un-
acceptable adverse event.
PK assay and sampling
For the PK analysis, the serum cetuximab concentra-
tion was measured by an enzyme-linked immunosorbent 
assay.7 Figure 1b illustrates the sampling schedules in the 
two studies.
In the PhI trial, PK samples were taken before and at the 
end of the first cetuximab infusion, as well as at minimum 
cetuximab concentrations (Cmin) until day 29. For the dos-
ing interval starting on day 29, dense sampling (Figure 1b) 
was performed as follows: patients receiving ADR (arm A) 
were sampled at the end of infusion and at 4, 24, 48, 96, and 
168 hours after the start of infusion, whereas patients in other 
treatment groups (arm B) were sampled at the end of infusion 
and at 4, 24, 48, 96, 168, 240, and 336 hours after the start 
of infusion. After the dense sampling interval, blood samples 
were collected at Cmin until the end of the study in both arms.
In the EVEREST trial, PK samples were taken before the 
first dose and at Cmin until week 29. In patients on ADR 
(groups A and C), dense sampling (at the end of infusion and 
6, 24, 48, 72, and 168 hours after the start of infusion) was 
performed over the dosing interval starting on day 29. The 
patients undergoing dose escalation (group B) were sam-
pled in such a way that five patients from each dose level 
were intensively sampled for one dosing interval, starting on 
the second dose of the dose level. After the dense sampling 
interval, Cmin samples were collected from all patients until 
the end of the study.
Population PK analysis
A population PK model was developed using the nonlin-
ear mixed-effects modeling approach. The data were 
analyzed using the Stochastic Approximation Expectation 
Maximization estimation method in NONMEM (version 
7.3.0), PsN (version 4.4.8), and Pirana (version 2.9.2), 
whereas R (version 3.3.2) and RStudio (version 1.1.456) 
were used for preprocessing and postprocessing of data. 
The “log-transform both sides” approach was used.
Confirmed by graphical analysis, we used the previously 
published two-compartment model.4,5 We investigated 
six elimination models from the central compartment: lin-
ear clearance (LCL),6 linear clearance with exponential 
change over time (TVARCL),9,10 Michaelis–Menten clear-
ance (MMCL),4 linear clearance and Michaelis-Menten 
(MMCL  +  LCL), linear clearance with exponential change 
over time and Michaelis–Menten (MMCL  +  TVARCL), and 
linear clearance and zero-order (LCL  +  0.EL)5 clearance 
(Figure 2a). The differential equations for the change of drug 
amount in the central compartment (parameters part of elim-
ination process marked in bold) were as follows:
where A1 denotes drug amount in central compartment; A2, 
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Figure 2 Overview of the analysis workflow. (a) Graphical representation of the investigated base pharmacokinetic (PK) models for 
cetuximab. (b) Flowchart illustrating the stochastic simulation and estimation (SSE) analysis per study design scenario. The final PK 
base (reference, “true”) model was used to simulate 200 data sets in the stochastic simulation step. The reference and five alternative 
models were subsequently fit to the simulated datasets. Thus, altogether 6 × 200 = 1,200 model fits were performed. For each model 
accuracy and bias of parameter estimates, exposure metrics (AUC and Cmin after the second dose and in steady state), and their bias 
and accuracy were calculated and compared. The process was repeated for four study designs in total differing in sampling density 
and number of dose levels. C1 denotes drug concentration in central compartment; C2, drug concentration in peripheral compartment; 
CL, linear clearance from central compartment; Imax, maximum change in time-varying linear clearance; Km, concentration at half Vmax; 
k0, zero-order rate constant of elimination from central compartment; ηImax, between-patient variability in Imax; Q, intercompartmental 
exchange rate; t50, time at which clearance is halved; Vmax, maximal rate of saturable elimination; γ, curve shape factor. Parts of the 
















Time-varying linear and Michaelis-
Menten (TVARCL+MMCL)














Central Peripheral Central Peripheral
Central Peripheral Central Peripheral Central Peripheral
Estimation Calculation


























CPT: Pharmacometrics & Systems Pharmacology
Clearance Models of Oncology Biotherapeutics
Grisic et al.
in central compartment; Q, intercompartmental exchange 
rate; CL, linear clearance from central compartment; Imax, 
maximum change in time-varying linear clearance; ηImax, be-
tween-patient variability in Imax; t50, time at which clearance is 
halved; γ, curve shape factor; Vmax, maximal rate of saturable 
elimination; Km, concentration at half Vmax; and k0, zero-order 
rate constant of elimination from central compartment.
The distribution of individual parameter values was as-
sumed to follow a log-normal distribution. For covariate 
model development, a full fixed-effects modeling approach 
was used, as proposed by Gastonguay,11 whereby prese-
lected covariates were simultaneously included in the final 
base model. The criteria for inclusion/exclusion of a covari-
ate comprised statistical relevance (null value not covered 
by confidence interval) and clinical relevance (difference 
in baseline linear CL greater than ± 25% relative to typical 
CL value), impact on between-subject variability reduction, 
and extent of covariate effect on model parameters. Model 
discrimination was based on plausibility and precision of pa-
rameter estimates, the Akaike information criterion (AIC),12 
goodness-of-fit plots, and visual predictive checks.
Study design investigations
In the second part of this analysis, implications of study 
designs, on the model performance and parameter iden-
tifiability were assessed. Using the final base PK model 
(MMCL + TVARCL) as a reference model, 200 data sets were 
simulated, each comprising 100 patients, making a total of 
20,000 virtual patients. The six investigated models were fit 
to the simulated data sets under four study-design scenar-
ios, using the stochastic simulation and estimation (SSE) PsN 
feature,13 amounting to a total of 4,800 model fits (Figure 2b).
The body surface area (BSA) of the virtual population of 100 
patients was sampled to correspond to the distribution of the 
clinical database (Table 1) and assumed to be constant over 
time. In all study designs, all virtual patients received the same 
initial cetuximab induction dose of 400  mg/m2 with infusion 
rate of 5 mg/min. The infusion rate for subsequent doses was 
10  mg/min. The 100 virtual patients were relegated to four 
study designs (A–D), which differed in sampling density (dense 
vs. sparse) and dose levels (single vs. multiple-dose levels) and 
were chosen to correspond to typical trial designs in the initial 
phases of drug development (A and B) and later (e.g., phase III 
trials (C and D)). The investigated study designs were as follows:
• Study design A, the virtual patients were stratified 
in order to ensure that all dose levels were present 
across the whole range of BSA. The patients were 
first stratified in four groups corresponding to the 
BSA quartiles in order to avoid having only low or 
only high doses in one BSA quartile. To achieve 
further randomization of the dose distribution, within 
each group the patients were further randomly strat-
ified to receive 200, 250, 300, 350, 400, 450, or 
500  mg/m2 every week starting from the second 
dose. In addition to the Cmin sampling described 
below, additional samples were taken after the fifth 
dose, at the end of infusion, and 4, 24, 48, 72, and 
96  hours after infusion start, corresponding to the 
clinical trials;
• Study design B, the virtual patients were treated ac-
cording to the approved dosing regimen of cetuximab 
(250  mg/m2 every week; i.e., single dose level). The 
sampling was performed in the same manner as in 
study design A;
• Study design C, the virtual patients were treated in the 
same manner as in study design A, and only Cmin sam-
ples were taken;
• Study design D, the virtual patients were treated ac-
cording to the approved dosing regimen of cetuximab 
(single dose level) and only Cmin samples were taken.
Under each study design, all virtual patients were sam-
pled at Cmin after each dose for 12 weeks. At week 12, the 
patients were separated into 5 groups of 20 patients. Each 
group was sampled once a month for 3 months, until a study 
duration of 18 months (Figure S1).
To assess the performance across the models, for each in-
vestigated study design, clinically relevant exposure metrics 
(Cmin and area under the curve (AUC)) as well as their bias 
and accuracy were calculated (Supplementary Material), 
in addition to the standard set of parameters provided by 
the PsN output (including parameter estimates and their bias 
and accuracy; Figure 2b). The PK metrics after the second 
dose and at steady-state (i.e., at the approximate time when 
90% of maximal CL decrease has occurred per the refer-
ence model (week 60)), were considered. The bias (i.e., mean 














Age, years 61 (26–81)
Duration of cetuximab therapy, months 5.8 (0.25–27.3)
Weight, kg 72 (41–132)
Body surface area, m2 1.85 (1.37–2.70)
Amphiregulin concentration, pg/mL 226 (8.50–5080)
Epidermal growth factor concentration, pg/mL 12.7 (0.61–633)
Interleukin 8 concentration, pg/mL 42.0 (1.76–5650)
Transforming growth factor-α concentration, pg/mL 2.52 (0.404–131)
Vascular endothelial growth factor concentration, 
pg/mL
278 (46.7–1720)
Creatinine clearance, mL/min 95.5 (31.0–218)
Categorical n (%)
Female 82 (36)





RECIST response achieved 63 (28)
ECOG, Eastern Cooperative Oncology Group; RAS, rat sarcoma proto-
oncogene; RECIST, Response Evaluation Criteria in Solid Tumors.
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where N denotes number of simulated trials repetitions 
(200); n, the number of patients (number of patients in a trial ∙ 
number of simulated trial repetitions; i.e., 200∙100 = 20,000); 
refi, the parameter/exposure metric values of an individual i 
for the reference PK (MMCL + TVARCL) model; and esti, the 
respective values for the alternative models (Cmin: individual 




In total, 3,821 PK samples from 226 patients (PhI (N = 62) 
and EVEREST (N = 164)) were analyzed. The relevant pa-
tient characteristics are given in Table 1. Based on AIC 
computed using Stochastic Approximation Expectation 
Maximization-importance sampling algorithm, the two- 
compartment model with parallel Michaelis–Menten 
and linear clearance that changes exponentially over 
time (MMCL  +  TVARCL) outperformed the second best 
model by 334 points for predicting the serum cetuximab 
concentration-time profiles in the analyzed population 
(Table 2). By decreasing the value of AIC, we found 
TVARCL, MMCL + LCL, MMCL, and LCL models, whereas 
the worst model was the one assuming elimination as 
first-order and zero-order mixed processes.
Parameter estimates for the investigated models are 
presented in Table 2. All fixed-effect parameters of the 
MMCL  +  TVARCL model showed excellent precision with 
relative standard error below 30%. Between-patient variabil-
ity in baseline linear CL, V1, V2, Vmax, and Imax was ≤ 61.3 
coefficient of variation with satisfactory shrinkage. As in-
dicated by goodness-of-fit plots (Figure S3), the model 
describes the clinical data well.
Covariate model
As body size is known to impact the PKs of mAbs,14 base-
line BSA was investigated for influence on baseline CL 
and volumes of distribution. The most appropriate imple-
mentation of baseline BSA was via power function with 
exponent fixed to 0.75 for CL and 1 for volumes of distribu-
tion.15 The inclusion of BSA decreased objective function 
value for ~ 60 points, and slightly decreased between-pa-
tient variability in baseline CL, V1, and V2 by 8.6%–11.8% 
(up to 5.4 percentage points, respectively), as well as ad-
ditive residual unexplained variability (4.85–4.68 µg/mL).
Based on biological and clinical relevance, the following 
covariates were preselected for full fixed-effect covariate 
Table 2 Comparison of all investigated base models
LCL TVARCL MMCL MMCL + LCL MMCL + TVARCL LCL + 0.EL
LCL, L/h (RSE%) 0.0222 (3) 0.0262 (3) - 0.0153 (4) 0.0174 (5) 0.0206 (-)
V1, L (RSE%) 3.84 (3) 3.67 (3) 3.75 (3) 3.71 (2) 3.65 (3) 3.82 (-)
Q, L/h (RSE%) 0.0188 (17) 0.0282 (12) 0.0332 (19) 0.0323 (4) 0.0368 (5) 0.0216 (-)
V2, L (RSE%) 3.38 (12) 1.65 (11) 2.67 (8) 3.25 (6) 2.65 (4) 3.31 (-)
KM, mg/L (RSE%) - - 283 (26) 9.81 (5) 13.3 (21) -
Vmax, mg/h (RSE%) - - 9.48 (17) 0.882 (5) 0.861 (5) -
Imax, % (RSE%) - –19.6 (16) - - –23.1 (20) -
T50, weeks (RSE%) - 7.26 (15) - - 20.5 (29) -
γ (RSE%) - 2.54 (24) - - 1 FIX -



























































- - - - - 150.3 (-)
[57]
Additive RUV, mg/L (RSE%) 9.44 (11) 7.79 (12) 8.14 (13) 5.85 (12) 4.85 (22) 8.65 (-)
Proportional RUV, CV% (RSE%) 23.1 (5) 22.8 (4) 23.4 (5) 24.0 (4) 23.5 (4) 22.9 (-)
AIC (SAEM-IMP) –6132 –6990 –6534 –6947 –7324 –5990
0.EL, zero-order elimination; AIC, Akaike information criterion; Imax, maximum change in time-varying clearance; K0, zero-order rate constant of elimination 
from central compartment; KM, Michaelis-Menten rate constant; LCL, linear clearance; MMCL, Michaelis-Menten clearance; η, between-patient variability; 
Q, intercompartmental exchange rate; RSE, relative standard error; RUV, residual unexplained variability; Shr, shrinkage; T50, time at which clearance is 
halved; TVARCL, time-varying linear clearance; V1, central volume of distribution; V2, peripheral volume of distribution; Vmax, maximum rate of saturable 
elimination; γ, curve shape factor.
The model exhibiting the best performance comprised parallel Michaelis–Menten and time-varying linear clearance (MMCL + TVARCL).
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modeling: patient-related factors (age, sex, RAS mutation 
status, and creatinine clearance), therapy-related factors 
(dose group and co-medication with irinotecan or 5-fluoro-
uracil/folic acid), and EGFR ligand and other disease-related 
measurements (serum concentration of amphiregulin, epi-
dermal growth factor, interleukin-8, transforming growth 
factor-α, vascular endothelial growth factor, and Eastern 
Cooperative Oncology Group performance status). None of 
the investigated covariates were statistically or clinically rel-
evant (Figure S2), thus the final model comprised only the 
effect of BSA described above.
Study design investigations
Parameter estimates of the reference model and their bias 
indicate that across study designs the reference model 
parameter estimates were the least biased (Table S2). 
However, bias of many parameters increased substantially 
in case of sparse sampling compared with rich sampling. 
The highest change is observed for Michaelis–Menten CL 
parameters, where changing to either single-dose level or 
sparse sampling resulted in substantial increase in the pa-
rameter bias. Median objective function value across model 
fit repetitions was lowest for the true (MMCL  +  TVARCL) 
model, suggesting that this model, in fact, resulted in 
the best fit from all investigated models, under all study 
designs. This was further confirmed by the highest percent-
age of cases. The reference (TVARCL + MMCL) model was 
chosen as the best based on the AIC value under all study 
designs; only a slight variation existed among different 
study designs, which followed the expected pattern: 93% 
in the case of the most informative study design (multiple 
dose levels and rich sampling) and 80% for the least infor-
mative study design (one dose level and sparse sampling).
As a reference “background” bias comparison, bias in 
Cmin and AUC from the reference model was calculated 
using simulated datasets as reference (horizontal lines in 
Figure 3 and Figure 4); as anticipated, this bias was of very 
low extent. Comparing the five alternatives to the reference 
MMCL + TVARCL) model, bias in Cmin at steady-state was 
consistently lower than bias for Cmin after the second dose 
for all models and across all investigated study designs 
(Figure 3). All alternative models, except for the MMCL 
model, resulted in a negligible bias in Cmin at steady-state. 
With respect to bias in Cmin after the second dose, the 
TVARCL model exhibited the smallest bias.
In study designs with rich sampling (A and B), bias in 
AUC after the second dose was consistently lower than 
bias in AUC at steady-state for all models (Figure 4). 
The TVARCL model resulted in the lowest bias for both 
exposure metrics. Compared with rich sampling, sparse 
sampling (study designs C and D) overall resulted in higher 
bias, especially in AUC after the second dose. Across all 
study designs and for both AUC metrics, the bias was the 
highest for the MMCL model. Overall, the impact of study 
design was more pronounced for bias in AUC than Cmin 
(Figure S7).
Altogether, changes in study design altered accuracy of 
the PK metrics to a lesser extent than bias (Figure S5 and 
Figure S6). Differences in inaccuracy of Cmin across study 
designs were minimal (< 1.5 µg/mL) and can be considered 
negligible (Figure S5). Study designs with a single-dose 
level (B and D) resulted in higher accuracy (lower root mean 
squared error) compared with multiple-dose level designs, 
regardless of the sampling density.
DISCUSSION
This study revealed that cetuximab CL is best described by 
parallel nonlinear and linear clearance that changes expo-
nentially over time. Rich sampling at steady-state was crucial 
for unbiased estimation of Michaelis–Menten elimination in 
case of the true (MMCL + TVARCL) model (Table S2).
New consolidated PK model of cetuximab
Due to the dataset combining rich and sparse data with 
multiple dose levels collected over more than 2 years, we 
have been able to identify, to the best of our knowledge 
for the first time, a complex approximated TMDD model of 
cetuximab with time varying clearance (MMCL + TVARCL). 
Cetuximab clearance was best described by a combina-
tion of Michaelis–Menten and linear CL components, thus 
demonstrating both exposure-dependency and time-de-
pendency of cetuximab PK, respectively. The nonlinear 
CL of a maximum rate of 0.861 mg/h was identified, with 
50% of maximum value reached at a drug concentration 
of 13.3 mg/L. Nonlinear CL at very low cetuximab concen-
trations (C<<Km) was approximately four times higher than 
baseline linear CL (0.0647 vs. 0.0174 L/h, respectively). In 
parallel, the linear CL component decreased exponentially 
with mean maximal decrease of ~ 18% (155% coefficient 
of variation), reaching 50% of the maximal decrease after 
~ 5 months of therapy.
Two previous analyses identified simpler population PK 
models for cetuximab,4,5 likely due to less informative data 
(i.e., lower number of patients and only one dose level). 
Azzopardi et al.5 investigated cetuximab PK in patients with 
colorectal cancer and found that clearance was best de-
scribed by the LCL + 0.EL model. Dirks et al.4 found that 
the Michaelis–Menten elimination was most appropriate to 
describe cetuximab clearance in patients with squamous 
cell carcinoma of the head and neck. They also investigated 
a potential time change in CL and found that cetuximab 
elimination was not time-dependent. The disagreement of 
our findings with the study by Dirks et al. might be due to 
differences in the investigated populations. The median du-
ration of cetuximab treatment was significantly shorter in the 
study by Dirks et al. (6 weeks) compared with our popula-
tion (~ 23 weeks), which might have resulted in insufficient 
informativeness of the data with respect to potential time 
change in CL.
We further found that disregarding either of the two CL 
components (i.e., considering only the time-varying linear 
CL or TMDD component) resulted in significantly inferior 
model performance compared with the model with both 
clearance components (as identified in the final PK model). 
For the final (MMCL + TVARCL) model, relative relevance of 
the different identified clearance components is illustrated in 
Figure S4. The linear pathway contributed to a larger extent 
to the total cetuximab clearance than the nonlinear one; ne-
glecting the change of clearance over time resulted in minor 
differences in the cetuximab concentration-time profile of a 
635
www.psp-journal.com
Clearance models of oncology biotherapeutics
Grisic et al.
typical patient. For a typical individual after the first dose 
under ADR, the nonlinear CL at Cmax (197  µg/mL) was 
0.00409, and at Cmin (48.3 µg/mL) 0.0139 L/h. Furthermore, 
the change of mAb CL over time has previously been related 
to disease status in patients with cancer,9,16 which is in ac-
cordance with our findings as explained below. Thus, the 
ability to identify the change of CL over time is dependent 
on disease status change (e.g., initial disease burden and 
magnitude of change) in the investigated time frame and 
population (i.e., if an investigated population exhibits no rel-
evant change in disease status, no change in CL over time 
is expected).
Study design investigations
The capacity to identify a more or less complex model is 
highly sensitive to the study design. Impact of study de-
sign on how well the data informs each model parameter 
can be assessed by comparing bias in parameter esti-
mates of the reference model across the study designs.17 
Our results (Table S2) suggest that, in study designs with 
single-dose levels and/or sparse sampling, the bias in 
parameters of Michaelis–Menten CL increases the most. 
This implies that data with only one dose level are less 
informative for nonlinear CL, which is expected because 
this CL component is relevant only for the lower expo-
sure range, and might not be captured with only single 
level dosing. On the other hand, our findings suggest that 
sparse sampling does not provide enough information to 
estimate all the parameters, even if multiple-dose level 
data are available (Table S2).
Both rich and sparse sampling designs were investigated 
to assess bias and accuracy of parameter estimates and 
derived exposure metrics. The sampling density was found 
to be a more influential factor than number of dose levels. 
Figure 3 Bias in minimum concentration after the second (Cmin2) dose and Cmin in steady–state (CminSS) compared with reference 
MMCL + TVARCL model. (a) Study design A: multiple-dose levels and rich sampling. (b) Study design B: single-dose level and rich 
sampling. (c) Study design C: multiple-dose levels and sparse sampling. (d) Study design D: single-dose level and sparse sampling. 
Horizontal lines represent “background” bias for the reference model compared with the simulated observations. 0.EL, zero-order 
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Our results indicate that the effect of study design depends 
on the PK metric considered. For instance, having sparse 
instead of dense sampling in the TVARCL model resulted 
in similar (or even slightly decreased) bias in Cmin, whereas 
the bias in AUC increased substantially. This is because the 
investigated sparse sampling study designs consisted of 
only Cmin samples and thus did not inform the earlier part 
of the PK curve (especially Cmax) essential for AUC calcula-
tion. Additional sampling at Cmax in addition to Cmin samples 
should reduce the bias in AUC. On the other hand, bias in 
AUC was lower for all investigated models in single-dose 
level designs compared with multidose level designs, and a 
similar trend is observed for bias in Cmin.
Altogether, our findings imply that the TVARCL model is 
the best overall approximation to the true (MMCL + TVARCL) 
model. In study design A, in which the AUC calculation is 
well informed due to rich sampling and the role of nonlinear 
CL is expected due to low dose levels, the TVARCL model 
resulted in overprediction of Cmin after the second dose. 
This behavior is mechanistically expected, as the contri-
bution of Michaelis–Menten CL, which is not accounted for 
in this model, is more important for Cmin than the AUC cal-
culation, and it is expected to be more pronounced in the 
earlier phase of therapy (i.e., after the second dose) before 
the decrease of linear CL becomes significant and when the 
accumulation of the drug is not pronounced.
Mechanisms of clearance change
The role of nonlinear CL in disposition of mAbs has been 
well-established and is mechanistically explained by the 
presence of TMDD.2,18,19 On the other hand, time depen-
dence of PK of mAbs has only recently come into focus and 
Figure 4 Bias in AUC after the second dose and AUC in steady-state compared with reference MMCL + TVARCL model. (a) Study 
design A: multiple-dose levels and rich sampling. (b) Study design B: single-dose level and rich sampling. (c) Study design C: multiple-
dose levels and sparse sampling. (d) Study design D: single-dose level and sparse sampling. Horizontal lines represent “background” 
bias for the reference model compared to the individual predictions from the original, reference model, used for simulations. AUC, area 
under the curve; AUCss, area under the curve in steady-state; 0.EL, zero-order clearance; LCL, linear clearance; MMCL, Michaelis-
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the understanding of its origin remains hypothetical. Time-
dependent elimination has previously been described for 
mAbs indicated in oncology.9,10,16,20
To investigate potential reasons for the CL change, 
the time-varying CL component in responders and non-
responders to cetuximab therapy was compared. The 
response was defined as per Response Evaluation Criteria 
in Solid Tumors (RECIST).21 Patients with complete or 
partial response were classified as responders, whereas 
patients with stable or progressive disease were classified 
as nonresponders. The average magnitude of decrease 
in CL was higher in responders than in nonresponders 
(Figure 5), implying that CL change is related to post-treat-
ment disease status in these patients, in accordance with 
previously reported findings.9,16,22 Mechanistically, the ef-
fect of disease status might comprise changes in TMDD 
(lower target abundance in responders) and/or cancer-re-
lated cachexia (lower protein turnover in responders).20 
Due to inflammation, the protein turnover rate in patients 
with cancer is increased compared with that in healthy 
individuals, as indicated by measures such as decreased 
albumin concentration.2 Decrease over time in disease 
(and thus inflammatory) status will be reflected in normal-
ization of protein turnover rate, that would, in turn, lead 
to decrease in nonspecific (linear) elimination of therapeu-
tic proteins, including cetuximab. We identified an initial 
decrease in cetuximab CL in both groups of patients, 
although it is of a lower extent in nonresponders than re-
sponders (Figure 5). Krippendorff et al.23 demonstrated 
that upon administration of an anti-EGFR drug, there is a 
steep initial decrease in receptor activation due to block-
age by the drug, followed by a gradual increase as drug 
exposure decreases. At high drug doses, a complete and 
long-lasting saturation of the target can be accomplished. 
Regardless of the outcome of the treatment (i.e., whether 
a patient is a responder or nonresponder), this initial effect 
is expected to be observed. In responders, further decline 
in CL over time is expected due to mechanisms elabo-
rated above. However, in nonresponders, the increase in 
disease burden would over time prevail, resulting in a net 
increase in CL.
Exposure-response and therapeutic drug monitoring
The findings of time-dependent change of cetuximab 
elimination in this study underline the bidirectional PK-PD 
relationship, which is intuitively anticipated for mAbs. 
The bidirectional interaction between PK and PD has 
important implications on assumption of exposure-re-
sponse causality and thus exposure-response analyses. 
In traditional exposure-response analyses, a unidirectional 
exposure-response relationship is assumed (i.e., exposure 
is considered the independent variable). However, in the 
presence of the time-dependent changes in elimination 
that are related to the patient response, this assumption 
fails to hold true, as response impacts exposure. As a con-
sequence, in this case, the exposure-response relationship 
is overestimated compared with the true underlying rela-
tionship.2,22 Thus, in the case of drugs with time-varying 
elimination, assumptions underlying therapeutic drug 
monitoring might be shattered. In addition, identifying 
and accounting for baseline biomarkers for disease status 
(e.g., cachexia24) would help to overcome these limitations.
In conclusion, a two-compartment model with parallel 
Michaelis–Menten and linear CL that changes exponen-
tially over time best characterized the PK of cetuximab. The 
magnitude of decrease in clearance over time is higher for 
responders than nonresponders, calling for better under-
standing of exposure-response analyses and therapeutic 
drug monitoring in the presence of time-varying clearance. 
Furthermore, the importance of informing the population 
models with rich data is stressed, supporting analysis of 
pooled data from multiple trials at later stages of drug devel-
opment instead of using only sparse data (e.g., in the case 
of phase III clinical trials).
Supporting Information. Supplementary information accompa-
nies this paper on the CPT: Pharmacometrics & Systems Pharmacology 
website (www.psp-journal.com).
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